PMV Pharmaceuticals, Inc.
PMVP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001699382
No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q2 2026, worth $45.9M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding PMV Pharmaceuticals, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 69 | 64 | −5 |
| Shares | 37.0M | 34.3M | −2.68M (−7.3%) |
| Value | $45.8M | $45.9M | +$92.8K (+0.2%) |
New holders (4)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| MAI Capital Management | 133,122 | $178.4K | 0.00% |
| HRT Financial LP | 50,510 | $67.0K | 0.00% |
| Cooper/Haims Advisors, LLC | 39,021 | $52.3K | 0.02% |
| Susquehanna International Group, LLP | 37,531 | $50.3K | 0.00% |
Sold out (9)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Longaeva Partners L.P. | 552,027 | $684.5K |
| Evoke Wealth, LLC | 133,122 | $165.1K |
| Velan Capital Investment Management LP | 73,000 | $90.5K |
| Point72 Asset Management, L.P. | 20,945 | $26.0K |
| Gsa Capital Partners LLP | 15,441 | $19.0K |
| Virtu Financial LLC | 14,050 | $17.0K |
| Ameriprise Financial Inc | 13,237 | $16.4K |
| GTS Securities LLC | 10,001 | $12.4K |
| Simplex Trading, LLC | 8,181 | $10.1K |